<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="131673">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01387815</url>
  </required_header>
  <id_info>
    <org_study_id>P12-678</org_study_id>
    <nct_id>NCT01387815</nct_id>
  </id_info>
  <brief_title>Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Psoriasis</brief_title>
  <acronym>Complete-PS</acronym>
  <official_title>Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie (prior sponsor, Abbott)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cato Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>JSS Medical Research Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current study will compare the real - life effectiveness of adalimumab to topical and
      traditional systemic agents in the management of psoriasis and its impact on the patient's
      quality of life and societal burden of illness.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The physician global assessment (PGA) of of &quot;0&quot; or &quot;1&quot; indicating clear or minimal disease according to the classification below.</measure>
    <time_frame>6 month</time_frame>
    <description>Classification: 0-Clear, 1-Minimal, 2-Mild, 3-Moderate, 4-Severe, 5-Very Severe.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to achieving physician global assessment (PGA) â‰¤ 1</measure>
    <time_frame>Every 3 months up to 6 months, then every 6 months up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psoriasis and Arthritis Screening Questionnaire (PASQ)</measure>
    <time_frame>Every 3 months up to 6 months, then every 6 months up to 24 months</time_frame>
    <description>This is an 11 item tool that ascertains self reported presence of joint pain and swelling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Assessment of Disease Activity based on a six point Likert Scale</measure>
    <time_frame>Every 3 months up to 6 months, then every 6 months up to 24 months</time_frame>
    <description>Classification: Clear, Minimal, Mild, Moderate, Severe, Very Severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dermatology Quality of Life Index (DLQI)</measure>
    <time_frame>Every 3 months up to 6 months, then every 6 months up to 24 months</time_frame>
    <description>Self administered questionnaire comprised of 10 items assessing a patient's skin and problems associated with skin disease.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">660</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Topical Agents</arm_group_label>
    <description>patients with a new topical agent that was not used before or already on treatment with a topical agent and not responding</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Traditional Systemic Agents</arm_group_label>
    <description>patients with a new systemic agent that was not used before alone or in combination with topical agents</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adalimumab</arm_group_label>
    <description>patients with adalimumab alone or in combination with topical agents</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Offices of community dermatologists
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Active moderate or severe Plaque PS according to the judgment of the treating
             physician.

          -  The treating physician has decided to change the current treatment or add additional
             treatments for any reason including but not limited to inadequate response,
             intolerance, sub-optimal compliance or patient preference.

        Exclusion Criteria:

          -  Currently participating in another prospective study with similar objectives.

          -  Patient cannot or will not sign informed consent.

          -  Presence of other condition that, in the opinion of the treating physician, prohibits
             the patient from participating in the study or obscures the assessment of the
             treatment of Plaque PS.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christina Pelizon, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SimcoDerm Medical and Surgical Dermatology Center /ID# 96915</name>
      <address>
        <city>Barrie</city>
        <zip>L4M 7G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maritime Medical Reseach Center /ID# 128775</name>
      <address>
        <city>Bathurst</city>
        <zip>E2A 4Z9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Jason Ronald Sneath Medical Corporation /ID# 138026</name>
      <address>
        <city>Brandon,</city>
        <zip>R7A 0L5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kirk Barber Research, Calgary, Alberta, Canada /ID# 57722</name>
      <address>
        <city>Calgary</city>
        <zip>T2G 1B1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Richmond Road Diagnostic Treatment Centre /ID# 70913</name>
      <address>
        <city>Calgary</city>
        <zip>T2T 5C7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Skin Advancement Inc. /ID# 66782</name>
      <address>
        <city>Calgary</city>
        <zip>T3A 2N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Isabelle Delorme Inc. /ID# 57791</name>
      <address>
        <city>Drummondville</city>
        <zip>J2B 5L4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Nakatsui P.C. /ID# 55080</name>
      <address>
        <city>Edmonton</city>
        <zip>T5N 4B2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alberta Laser and Dermatology Centre /ID# 75513</name>
      <address>
        <city>Edmonton</city>
        <zip>T6G 1C3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kingsway Clinical Research /ID# 97255</name>
      <address>
        <city>Etobicoke</city>
        <zip>M8X 1Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Irina Turchin PC Inc. /ID# 66029</name>
      <address>
        <city>Fredericton</city>
        <zip>E3B 1G9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Canada Cutaneous Research Associates Ltd. /ID# 46353</name>
      <address>
        <city>Halifax</city>
        <zip>B3H 1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatrials Research Inc. /ID# 124138</name>
      <address>
        <city>Hamilton</city>
        <zip>L8N 1Y2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Wei Jing Loo Medicine Professional Corporation /ID# 127546</name>
      <address>
        <city>London</city>
        <zip>N6H 5L5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynderm Research Inc. /ID# 63206</name>
      <address>
        <city>Markham</city>
        <zip>L3P 1X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Regional Wound Healing Clinic /ID# 55135</name>
      <address>
        <city>Mississauga</city>
        <zip>L4Y 1A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Anna Hinek Medicine Profesional Corporation /ID# 148305</name>
      <address>
        <city>Mississauga</city>
        <zip>L5M 2V8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatologue Inc. /ID# 76074</name>
      <address>
        <city>Moncton</city>
        <zip>E1C 8X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellington Medical Clinic Ltd. /ID# 55083</name>
      <address>
        <city>Nanaimo</city>
        <zip>V9T 1W1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oakville Dermatology and Laser Center /ID# 55130</name>
      <address>
        <city>Oakville</city>
        <zip>L6J 7W5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Melinda Gooderham Medicine Professional Corporation /ID# 54566</name>
      <address>
        <city>Peterborough,</city>
        <zip>K9J 5K2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mitsos, Pierrefonds, CA /ID# 124156</name>
      <address>
        <city>Pierrefonds</city>
        <zip>H8Z 1W5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Douglas N. Keeling MD Dermatologist PC /ID# 55098</name>
      <address>
        <city>Quispamsis</city>
        <zip>E2E 4Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>York Dermatology Center /ID# 127786</name>
      <address>
        <city>Richmond Hill</city>
        <zip>L4C 9M7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dre. Angelique Gagne-Henley M.D. Inc. /ID# 125204</name>
      <address>
        <city>Saint-Jerome</city>
        <zip>J7Z 3B8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal University Hospital, Saskatoon, SK, Canada /ID# 74613</name>
      <address>
        <city>Saskatoon</city>
        <zip>S7N 0W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specialized Dermatology Inc. /ID# 64031</name>
      <address>
        <city>St-Catharines</city>
        <zip>L2R 5W4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karma Clinical Trials /ID# 55101</name>
      <address>
        <city>St. John's</city>
        <zip>A1A 4Y3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nexus Clinical Research /ID# 56403</name>
      <address>
        <city>St. John's</city>
        <zip>A1A 5E8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Lyne Giroux, Sudbury, CA /ID# 55128</name>
      <address>
        <city>Sudbury</city>
        <zip>P3C 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lori Shapiro Medicine Professional Incorporation /ID# 55126</name>
      <address>
        <city>Thornhill</city>
        <zip>L4J 3M6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Dermatology Centre /ID# 55127</name>
      <address>
        <city>Toronto</city>
        <zip>M3H 5Y8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatologie Sima Inc. /ID# 54922</name>
      <address>
        <city>Verdun</city>
        <zip>H4G 3E7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Percuro Clinical Research, Ltd. /ID# 54563</name>
      <address>
        <city>Victoria</city>
        <zip>V8V 3M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Beatrice Wang /ID# 63242</name>
      <address>
        <city>Westmount</city>
        <zip>H3Z 2S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winnipeg Clinic, Manitoba, Canada /ID# 56865</name>
      <address>
        <city>Winnipeg</city>
        <zip>R3C 0N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://rxabbvie.com</url>
  </link>
  <verification_date>April 2017</verification_date>
  <lastchanged_date>April 5, 2017</lastchanged_date>
  <firstreceived_date>July 1, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adalimumab</keyword>
  <keyword>Psoriasis</keyword>
  <keyword>Topical Agents</keyword>
  <keyword>Observational</keyword>
  <keyword>Traditional Systemic Agents</keyword>
  <keyword>Prospective</keyword>
  <keyword>Comparative</keyword>
  <keyword>Effectiveness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
